Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Avient reflects 2023 adjusted EBITDA guidance of $530M and estimated run-rate CAPEX of $110M. Avient Specialty Other Specialty / 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 MULTIPLE EXPANSION Avient Specialty Other Specialty / Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89.

APPLICATION BULLETIN Copyright © 2021, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. Contact your Avient sales representative for more information.

www.avient.com Copyright © 2020, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. www.avient.com Copyright © 2020, Avient Corporation.

www.avient.com Copyright © 2020, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. www.avient.com Copyright © 2020, Avient Corporation.

AVIENT SOLUTION ADDRESSES CRITICAL MANUFACTURING PRODUCTIVITY ISSUES AND DELIVERS OVER $100,000 PER YEAR IN SAVINGS Avient helped the customer calculate costs for the 12-month period. With the Avient material, the manufacturer is expected to save $122,000 per year vs. silicone.

Copyright © 2022, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. Avient is committed to the needs of our healthcare customers.

Copyright © 2023, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. Avient is committed to the needs of our healthcare customers.

THE SOLUTION Seeking a way to address these challenges, the manufacturer consulted Avient. In a relatively short time, the Avient team was able to formulate additives that performed well at lower LDRs. Finally, Avient’s willingness and ability to conduct and provide testing results saved the customer time and money.

Patterson, Chairman, President, and Chief Executive Officer, Avient Corporation. The comprehensive publication is issued in advance of Avient’s upcoming Sustainability Day to be held on September 20, 2023. To access Avient’s news library online, please visit www.avient.com/news.

Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. F X ) -10% -11% -3% -12% 15 Avient ex. Avient Specialty Other Specialty / 2023E(%) 37 79 89 83 81 76 73 90 82 77 76 74 70 58 22 MULTIPLE EXPANSION Avient Specialty Other Specialty / Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $36.50.